Skip to content

US · SNGX · BIOTECHNOLOGY

Soligenix, Inc. (SNGX) intrinsic value and stock valuation

$0.22as of 2026-11-21 · Mkt cap 5.81M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Soligenix, Inc. DCF and intrinsic value

InvestorsCraft values SNGX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SNGX’s statements →

Soligenix, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Princeton, NJ 08540 soligenix.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-11.08M
20112025
Free cash flow
-$-10.27M
20112025
Total equity
$5.29M+7.2% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$250K$30K
Operating income-$-11.85M-$-9.44M-$-7.7M-$-14.24M-$-13.1M
Net income-$-11.08M-$-8.27M-$-6.14M-$-13.8M-$-12.55M
EPSd-$-2.13M-$-4.98M-$-12.79M-$-76.67M-$-66.05M
Operating cash flow-$-10.27M-$-8.4M-$-8.6M-$-12.65M-$-11.74M
Capital expenditure-$-10K$0.00$0.00-$-10K-$-10K
Free cash flow-$-10.27M-$-8.4M-$-8.6M-$-12.66M-$-11.75M
Total assets$9.24M$8.97M$9.8M$14.3M$26.9M
Total debt$360K$1.48M$3.49M$10.2M$9.96M
Net debt-$-7.58M-$-6.33M-$-4.95M-$-3.12M-$-16.08M
Total equity$5.29M$4.12M$2.52M-$-2.47M$10.7M
Cash and short-term investments$7.94M$7.82M$8.45M$13.4M$26M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$250K$30K
Cost of revenue$0.00$120K$740K$550K$730K
Gross profit$0.00-$-120K-$-740K-$-300K-$-700K
Research and development expenses$7.49M$5.22M$3.31M$7.94M$8.19M
Selling, general and administrative expenses$4.36M$4.22M$4.48M$6.69M$5.01M
Other expenses$0.00-$-120K-$-840K-$-700K-$-790K
Operating expenses$11.9M$9.32M$6.96M$13.9M$12.4M
Cost and expenses$11.9M$9.44M$7.7M$14.5M$13.1M
Interest income$270K$210K$0.00$0.00$0.00
Interest expense$0.00$0.00$50K$820K$900K
Depreciation and amortization$0.00$10K$10K$20K$30K
Ebitda-$-11.58M-$-9.46M-$-7.67M-$-14.11M-$-12.48M
Operating income-$-11.85M-$-9.44M-$-7.7M-$-14.24M-$-13.1M
Total other income/expenses, net$260K$760K-$-210K-$-710K-$-320K
Income before tax-$-11.59M-$-8.68M-$-7.91M-$-14.95M-$-13.42M
Income tax expense-$-510K-$-410K-$-1.77M-$-1.15M-$-860K
Net income-$-11.08M-$-8.27M-$-6.14M-$-13.8M-$-12.55M
Weighted average shares outstanding$5.19M$1.66M$480K$180K$190K
Weighted average diluted shares outstanding$5.19M$1.66M$480K$180K$190K
Balance sheet
20252024202320222021
Cash and short-term investments$7.94M$7.82M$8.45M$13.4M$26M
Net receivables$0.00$0.00$200K$220K$240K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$8.85M$8.83M$9.51M$13.9M$26.6M
Property, plant and equipment, net$350K$120K$240K$360K$130K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$390K$140K$290K$430K$300K
Total assets$9.24M$8.97M$9.8M$14.3M$26.9M
Accounts payable$1.12M$670K$1.11M$3.87M$2.93M
Short-term debt$110K$1.48M$2.37M$10M$110K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$3.7M$4.85M$6.15M$16.5M$6.29M
Long-term debt$240K$0.00$1.12M$230K$9.86M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$240K$0.00$1.12M$230K$9.86M
Capital lease obligations$360K$110K$230K$340K$110K
Total liabilities$3.94M$4.85M$7.27M$16.8M$16.2M
Common stock$10K$0.00$10K$0.00$0.00
Retained earnings-$-245.05M-$-233.97M-$-225.7M-$-219.56M-$-205.77M
Accumulated other comprehensive income (loss)$50K$50K$20K$20K$40K
Total equity$5.29M$4.12M$2.52M-$-2.47M$10.7M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$360K$1.48M$3.49M$10.2M$9.96M
Net debt-$-7.58M-$-6.33M-$-4.95M-$-3.12M-$-16.08M
Cash flow statement
20252024202320222021
Net income-$-11.08M-$-8.27M-$-6.14M-$-13.8M-$-12.55M
Depreciation and amortization$0.00$10K$10K$20K$30K
Stock-based compensation$590K$330K$370K$330K$360K
Change in working capital$30K-$-350K-$-3.44M$430K$650K
Accounts receivable$0.00$220K$30K$20K$60K
Inventory$0.00$0.00$0.00$0.00-$-1.13M
Accounts payable-$-20K-$-490K-$-2.69M$400K$1.13M
Net cash provided by operating activities-$-10.27M-$-8.4M-$-8.6M-$-12.65M-$-11.74M
Investments in property, plant and equipment-$-10K$0.00$0.00-$-10K-$-10K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-10K$0.00$0.00-$-10K-$-10K
Common stock issued$12.5M$5.81M$11.6M$80K$19.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$10.4M$7.76M$3.66M$80K$19.1M
Net change in cash$120K-$-630K-$-4.91M-$-12.68M$7.37M
Cash at end of period$7.94M$7.82M$8.45M$13.4M$26M
Operating cash flow-$-10.27M-$-8.4M-$-8.6M-$-12.65M-$-11.74M
Capital expenditure-$-10K$0.00$0.00-$-10K-$-10K
Free cash flow-$-10.27M-$-8.4M-$-8.6M-$-12.66M-$-11.75M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Soligenix, Inc.

        Soligenix, Inc., a biopharmaceutical firm in its advanced development stages, concentrates on bringing innovative products to market within the United States, specifically targeting rare illnesses. The company's operations are divided into two main divisions: Specialized BioTherapeutics and Public Health Solutions. Within the Specialized BioTherapeutics division, Soligenix is advancing SGX301 (marketed as HyBryte), a novel photodynamic treatment that has successfully completed its Phase III clinical trials for managing cutaneous T-cell lymphoma. This segment also includes SGX942, an innate defense regulator technology currently undergoing Phase III trials for various inflammatory conditions, notably oral mucositis in patients with head and neck cancer. Additionally, this division is pursuing proprietary oral formulations of beclomethasone 17,21-dipropionate designed to prevent or treat severe inflammatory gastrointestinal disorders, such as SGX203 for pediatric Crohn's disease. Another candidate, SGX302, is currently in Phase I/II clinical development for addressing mild-to-moderate psoriasis. The Public Health Solutions segment is dedicated to developing several critical assets. These include RiVax, a vaccine candidate against ricin toxin, which has successfully completed Phase Ia and Ib clinical evaluations; SGX943, a therapeutic agent in pre-clinical studies aimed at combating antibiotic-resistant and emerging infectious diseases; ThermoVax, an early-stage technology focused on enhancing vaccine thermostability; and CiVax, a pre-clinical vaccine candidate intended for COVID-19 prevention. Soligenix, Inc. was originally established as DOR BioPharma, Inc. before adopting its current name in 2009. Founded in 1987, the company maintains its corporate headquarters in Princeton, New Jersey.

        CEO
        Christopher J. Schaber
        Employees
        14
        Beta
        1.92

        Explore

        Frequently asked questions

        What is the intrinsic value of Soligenix, Inc. (SNGX)?

        InvestorsCraft does not currently publish an intrinsic value for SNGX. How the IC value is calculated.

        Is SNGX undervalued?

        InvestorsCraft does not publish an undervaluation signal for SNGX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.